Britain's GlaxoSmithKline has asked its shareholders to vote at a meeting on December 18 on its proposed major deal with Switzerland's Novartis, which will see the two pharmaceutical group trade more than $20 billion of assets.
The transaction, which includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer healthcare, was unveiled in April.
In a letter to shareholders endorsing the deal, GSK's Chairman Christopher Gent said approval would strengthen its franchises in vaccines and consumer healthcare to complement its leading position in respiratory and HIV.
"This is the most significant transaction for the company since the creation of GlaxoSmithKline in 2000," he said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.